Here are the DEF 14A proxy statements from GeoVax Labs, Inc. Warrants (GOVXW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 17, 2026 and asks holders to vote on director elections and seven proposals, including stockholder approval to issue shares upon exercise of warrants issued in February, March and May 2026.
The proxy materials fix April 20, 2026 as the record date; as disclosed, there were 2,892,570 shares outstanding as of April 20, 2026. The Board recommends votes FOR election of seven director nominees and FOR the issuance of shares upon exercise of the February 2026, March 2026 and May 2026 warrants, ratification of the independent auditor, and advisory votes on executive compensation.
GeoVax Labs, Inc. is calling a June 17, 2026 annual stockholder meeting in Atlanta to elect seven directors, approve two key warrant-exercise share issuances, ratify its independent auditor, and hold advisory votes on executive pay and the future frequency of say‑on‑pay votes.
The proxy details board structure, director and executive biographies, compensation, equity plans, and large 2025–2026 capital raises using common stock, pre‑funded warrants, and common warrants, including new February and March 2026 warrant structures that require stockholder approval before full exercise.